Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spriggs

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Gynecologic Oncology|June 17, 2008
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancerJason Konner, Russell J Schilder, Felicia A DeRosa, et al.
Cancer|February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation ProgramAlexander Drilon, Anne A Eaton, Katja Schindler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated ToxicitiesAnne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Early detection and prognosis of ovarian cancer using serum YKL-40Jakob Dupont, Meena K Tanwar, Howard T Thaler, et al.
Gynecologic Oncology|May 9, 2006
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective studyMika A Sovak, Martee L Hensley, Jakob Dupont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2007
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasCarol Aghajanian, Howard A Burris, Suzanne Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumorsWilliam P Tew, Michael Gordon, John Murren, et al.
Scientific Reports|February 13, 2021
Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignanciesMarina Stasenko, Evan Smith, Oladapo Yeku, et al.
Plos One|May 13, 2015
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor InvasionThapi D Rao, Huasong Tian, Xun Ma, et al.
American Journal of Clinical Oncology|November 24, 2021
Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal BrachytherapyAndrea L Russo, Larissa J Lee, Jennifer Y Wo, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology|June 17, 2008
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancerJason Konner, Russell J Schilder, Felicia A DeRosa, et al.
Cancer|February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation ProgramAlexander Drilon, Anne A Eaton, Katja Schindler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated ToxicitiesAnne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Early detection and prognosis of ovarian cancer using serum YKL-40Jakob Dupont, Meena K Tanwar, Howard T Thaler, et al.
Gynecologic Oncology|May 9, 2006
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective studyMika A Sovak, Martee L Hensley, Jakob Dupont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2007
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasCarol Aghajanian, Howard A Burris, Suzanne Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumorsWilliam P Tew, Michael Gordon, John Murren, et al.
Scientific Reports|February 13, 2021
Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignanciesMarina Stasenko, Evan Smith, Oladapo Yeku, et al.
Plos One|May 13, 2015
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor InvasionThapi D Rao, Huasong Tian, Xun Ma, et al.
American Journal of Clinical Oncology|November 24, 2021
Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal BrachytherapyAndrea L Russo, Larissa J Lee, Jennifer Y Wo, et al.
Pageof 7